当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.

The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study.

Abstract：

:In this open-label randomized clinical trial, HLA-identical sibling-matched hematopoietic stem cells (HSC) were transplanted (non-MSCs group, n=15) or cotransplanted with mesenchymal stem cells (MSCs) (MSCs group, n=10) in hematologic malignancy patients. The median number of MSCs infused was 3.4 x 10(5) kg(-1) (range, 0.3-15.3 x 10(5) kg(-1)). MSCs infusions were well tolerated. The median time to neutrophil engraftment (absolute neutrophil count >0.5 x 10(9) l(-1)) was 16 days for MSCs group and 15 days for non-MSCs group. The median time to platelet engraftment (platelet count >50 x 10(9) l(-1)) was 30 and 27 days, respectively. Grades II-IV acute graft-versus-host disease (GVHD) was observed respectively, in one (11.1%) and eight (53.3%) evaluable patients. Chronic GVHD was found in one (14.3%) and four (28.6%) evaluable patients. The number of patients who relapsed were six (60.0%) and three (20.0%), and the 3-year disease-free survivals were 30.0 and 66.7%, respectively. Thus cotransplantation of MSCs and HSCs may prevent GVHD, but the relapse rate is obviously higher than the control group. We conclude that use of MSCs must be handled with extreme caution before a large-scale clinical trial is performed.

journal_name

Leukemia

journal_title

Leukemia

authors

Ning H,Yang F,Jiang M,Hu L,Feng K,Zhang J,Yu Z,Li B,Xu C,Li Y,Wang J,Hu J,Lou X,Chen H

doi

10.1038/sj.leu.2405090

subject

Has Abstract

pub_date

2008-03-01 00:00:00

pages

593-9

issue

3

eissn

0887-6924

issn

1476-5551

pii

2405090

journal_volume

22

pub_type

杂志文章,随机对照试验

相关文献

LEUKEMIA文献大全
  • Late intensification with POMP chemotherapy prolongs survival in acute myelogenous leukemia--results of a Southwest Oncology Group study of rubidazone versus adriamycin for remission induction, prophylactic intrathecal therapy, late intensification, and l

    abstract：:Between August 1978 and September 1982, 642 patients with newly diagnosed acute myelogenous leukemia (AML) were entered onto a Southwest Oncology Group Study which addressed four questions. (i) What is the comparative utility of rubidazone versus adriamycin in remission induction? (ii) What is the role of prophylactic...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Morrison FS,Kopecky KJ,Head DR,Athens JW,Balcerzak SP,Gumbart C,Dabich L,Costanzi JJ,Coltman CA,Saiki JH

    更新日期：1992-07-01 00:00:00

  • De novo gene mutations in normal human memory B cells.

    abstract：:In the past years, the genomes of thousands of tumors have been elucidated. To date however, our knowledge on somatic gene alterations in normal cells is very limited. In this study, we demonstrate that tetanus-specific human memory B lymphocytes carry a substantial number of somatic mutations in the coding regions of...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-018-0289-4

    authors： Slot LM,Wormhoudt TAM,Kwakkenbos MJ,Wagner K,Ballering A,Jongejan A,van Kampen ACM,Guikema JEJ,Bende RJ,van Noesel CJM

    更新日期：2019-05-01 00:00:00

  • Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

    abstract：:Insulin and insulin growth factor type 1 (IGF-1) and their receptors are closely related molecules, but both factors bind to the receptor of the other one with a weak affinity. No study has presently documented a role of insulin as a myeloma growth factor (MGF) for human multiple myeloma cells (MMCs), whereas many stu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.192

    authors： Sprynski AC,Hose D,Kassambara A,Vincent L,Jourdan M,Rossi JF,Goldschmidt H,Klein B

    更新日期：2010-11-01 00:00:00

  • Resistance to RadLV-induced leukemia: non-participation of splenic natural killer cells.

    abstract：:The phenotypic expression of genetically determined resistance to radiation leukemia virus (RadLV)-induced leukemia in mice has been shown to reside in the bone marrow. Because the bone marrow contains precursors of natural killer (NK) cells, known to play a role in retrovirally induced infections, and because these c...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： St-Pierre Y,Hugo P,Lemieux S,Lussier G,Potworowski EF

    更新日期：1988-08-01 00:00:00

  • Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

    abstract：:Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and causality has not been established. Patients with CML-CP from three randomized phase III studies...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.69

    authors： Giles FJ,Mauro MJ,Hong F,Ortmann CE,McNeill C,Woodman RC,Hochhaus A,le Coutre PD,Saglio G

    更新日期：2013-06-01 00:00:00

  • Effects of clinical combinations of antileukemic drugs on DNA ligase from human thymocytes and normal, stimulated, or leukemic lymphocytes.

    abstract：:Human DNA ligase was purified from different kinds of immunocompetent cells: thymocytes, normal and stimulated lymphocytes, blasts from ALL (Burkitt and non-T, non-B) and ANLL (M1, M2, and M5). Based upon the protocol for the treatment of these leukemias, the purified enzymes were assayed in the presence of routinely ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Lamballe F,Maniey D,Boscher MY,Fauchet R,le Prise PY,David JC

    更新日期：1988-06-01 00:00:00

  • B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express the CD5 T cell marker.

    abstract：:Though peripheral blood B cells from healthy sheep were known to be devoid of the CD5 T cell marker, it appears from our study that most B cells from bovine leukemia virus- (BLV) infected sheep with hematological disorders express both the CD5 marker and surface IgM. The possible meaning of this T cell marker expressi...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Letesson JJ,Mager A,Mammerickx M,Burny A,Depelchin A

    更新日期：1990-05-01 00:00:00

  • Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSF.

    abstract：:The current study was undertaken to search for differences in the biology of cytogenetic subgroups in patients with de novo acute myeloid leukemia (AML). In addition, factors influencing the metabolism of cytosine arabinoside (araC) as the key agent of antileukemic activity were assessed. Bone marrow aspirates from 91...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402029

    authors： Jahns-Streubel G,Braess J,Schoch C,Fonatsch C,Haase D,Binder C,Wörmann B,Büchner T,Hiddemann W

    更新日期：2001-03-01 00:00:00

  • Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.

    abstract：:Syk is a protein tyrosine kinase that couples B-cell receptor (BCR) activation with downstream signaling pathways, affecting cell survival and proliferation. Moreover, Syk is involved in BCR-independent functions, such as B-cell migration and adhesion. In chronic lymphocytic leukemia (CLL), Syk becomes activated by ex...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.24

    authors： Hoellenriegel J,Coffey GP,Sinha U,Pandey A,Sivina M,Ferrajoli A,Ravandi F,Wierda WG,O'Brien S,Keating MJ,Burger JA

    更新日期：2012-07-01 00:00:00

  • Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells.

    abstract：:CDCP1, a novel stem cell marker, is expressed in hematopoietic cell line K562 but not in Jurkat. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat. The reporter assa...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404312

    authors： Kimura H,Morii E,Ikeda JI,Ezoe S,Xu JX,Nakamichi N,Tomita Y,Shibayama H,Kanakura Y,Aozasa K

    更新日期：2006-09-01 00:00:00

  • Immunophenotypic features and configuration of immunoglobulin genes in hairy cell leukemia-Japanese variant.

    abstract：:Immunophenotypes and Ig gene rearrangements were investigated in 12 patients with a variant form of hairy cell leukemia (HCL) termed HCL-Japanese variant (HCL-J), and in an HCL-J-derived cell line. The leukemic cells of HCL-J characteristically showed the phenotype of CD20+, CD5-, CD10-, CD11c+, CD22+, CD24- and CD25-...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Yamaguchi M,Machii T,Shibayama H,Tokumine Y,Hara J,Yutsudo M,Yamada O,Klobeck HG,Kitani T

    更新日期：1996-08-01 00:00:00

  • Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.

    abstract：:Lovastatin is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the major regulatory enzyme of the mevalonate pathway. We have previously reported that lovastatin induces a significant apoptotic response in human acute myeloid leukemia (AML) cells. To identify the critical biochemic...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402196

    authors： Xia Z,Tan MM,Wong WW,Dimitroulakos J,Minden MD,Penn LZ

    更新日期：2001-09-01 00:00:00

  • Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study.

    abstract：:Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to dasatinib in patien...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1038/s41375-020-0805-1

    authors： Cortes JE,Jiang Q,Wang J,Weng J,Zhu H,Liu X,Hochhaus A,Kim DW,Radich J,Savona M,Martin-Regueira P,Sy O,Gurnani R,Saglio G

    更新日期：2020-08-01 00:00:00

  • Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.

    abstract：:Sorafenib, a novel drug for metastatic renal cancer, has broad-spectrum activity against multiple tyrosine kinases, including Raf-1, vascular endothelial growth factor receptor and platelet-derived growth factor receptor. However, little is known about its effects on the immune system. In this report, we examine the e...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2008.58

    authors： Zhao W,Gu YH,Song R,Qu BQ,Xu Q

    更新日期：2008-06-01 00:00:00

  • A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.

    abstract：:We report the results of a phase I dose escalation trial of the multikinase inhibitor sorafenib in relapsed and refractory acute leukemia patients using an intermittent dosing regimen. Fifteen patients with advanced leukemia (12 with acute myeloid leukemia, 2 with acute lymphoblastic leukemia, 1 with biphenotypic) and...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2010.132

    authors： Pratz KW,Cho E,Levis MJ,Karp JE,Gore SD,McDevitt M,Stine A,Zhao M,Baker SD,Carducci MA,Wright JJ,Rudek MA,Smith BD

    更新日期：2010-08-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

    abstract：:We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.101

    authors： Sobh M,Michallet M,Gahrton G,Iacobelli S,van Biezen A,Schönland S,Petersen E,Schaap N,Bonifazi F,Volin L,Meijer E,Niederwieser D,El Cheikh J,Tabrizi R,Fegeux N,Finke J,Bunjes D,Cornelissen J,Einsele H,Bruno B,Pott

    更新日期：2016-10-01 00:00:00

  • Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.

    abstract：:Less-intense remission induction regimens for adults with newly diagnosed acute myeloid leukemia (AML) aim to reduce treatment-related mortality (TRM), here defined as death within 4 weeks after starting induction therapy. This assumes that TRM rates are similar to the 15-20% observed 20 years ago. Herein we test this...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.176

    authors： Othus M,Kantarjian H,Petersdorf S,Ravandi F,Godwin J,Cortes J,Pierce S,Erba H,Faderl S,Appelbaum FR,Estey E

    更新日期：2014-02-01 00:00:00

  • FHL2 regulates hematopoietic stem cell functions under stress conditions.

    abstract：:FHL2, a member of the four and one half LIM domain protein family, is a critical transcriptional modulator. Here, we identify FHL2 as a critical regulator of hematopoietic stem cells (HSCs) that is essential for maintaining HSC self-renewal under regenerative stress. We find that Fhl2 loss has limited effects on hemat...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.254

    authors： Hou Y,Wang X,Li L,Fan R,Chen J,Zhu T,Li W,Jiang Y,Mittal N,Wu W,Peace D,Qian Z

    更新日期：2015-03-01 00:00:00

  • Evaluation of the impact of allogenic transplant in first remission on an unselected population of patients with acute myeloid leukaemia aged 15-55 years. The Northern Regional Haematology Group.

    abstract：:The aim of this study was to collect prospectively unselected, population-based data on young adults with acute myeloid leukaemia (AML) over a 9-year period and to evaluate the impact on survival of the introduction of allogeneic transplantation performed in first remission. The population within the Northern Region o...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章

    doi：

    authors： Proctor SJ,Taylor PR,Stark A,Carey PJ,Bown N,Hamilton PJ,Reid MM

    更新日期：1995-07-01 00:00:00

  • High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia.

    abstract：:We explored the relationship between time to relapse and different exposure variables (serum methotrexate (S-MTX) 23, 36 and 42 h after start of administration, MTX elimination time and leucovorin (LV) dose) during high-dose MTX (HDM) treatment of 445 children with acute lymphoblastic leukemia. MTX was infused at 5 g/...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2404404

    authors： Skärby TV,Anderson H,Heldrup J,Kanerva JA,Seidel H,Schmiegelow K,Nordic Society of Paediatric Haematology and Oncology (NOPHO).

    更新日期：2006-11-01 00:00:00

  • Somatic hypermutation targeting to intrinsic hotspots of immunoglobulin genes in follicular lymphoma and multiple myeloma.

    abstract：:In this study, we analyzed the targeting of the somatic hypermutation (SHM) mechanism at specific hotspot sequence motifs in the V(H) and Vkappa genes of 10 follicular lymphoma (FL) cases and the Vkappa and Vlambda genes of 11 kappa- and six lamda-light chain expressing multiple myeloma (MM) cases. These sequences wer...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402258

    authors： Belessi C,Stamatopoulos K,Stavroyianni N,Zoi K,Papadaki T,Kosmas C

    更新日期：2001-11-01 00:00:00

  • Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation.

    abstract：:Both conventional chimerism analysis (CCA) and lineage-specific chimerism analysis (LCA) have potential pitfalls as diagnostic means for the detection of minimal residual disease after allogeneic hematopoietic cell transplantation (aHCT). Therefore, the present study examines the results of both methods in order to de...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2403719

    authors： Zeiser R,Spyridonidis A,Wäsch R,Ihorst G,Grüllich C,Bertz H,Finke J

    更新日期：2005-05-01 00:00:00

  • Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.

    abstract：:We studied changes in peripheral blood and bone marrow biopsy specimens obtained before, during, and after recombinant alpha 2b-interferon (IFN-alpha 2b) therapy in 25 patients with hairy cell leukemia. During therapy, only 1 patient showed no improvement in at least one of the parameters monitored. Granulocytopenia, ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Bardawil RG,Ratain MJ,Golomb HM,Bitter MA,Groves C,Vardiman JW

    更新日期：1987-04-01 00:00:00

  • Establishment and characterization of a new erythropoietin-dependent acute myeloid leukemia cell line, AS-E2.

    abstract：:We have established an erythropoietin-dependent human leukemia cell line, AS-E2, from a patient with acute myeloid leukemia. These cells have many characteristics of late erythroid progenitor cells, they are positive for CD36, Glycophorin A, and CD71 but negative for CD41, and positive for benzidine and PAS staining. ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400838

    authors： Miyazaki Y,Kuriyama K,Higuchi M,Tsushima H,Sohda H,Imai N,Saito M,Kondo T,Tomonaga M

    更新日期：1997-11-01 00:00:00

  • Myeloid differentiation antigens identify leukemic cell subpopulations with different cell cycle characteristics.

    abstract：:In order to assess the proliferative capacity of leukemic subpopulations and to know whether it can be related to the stage of maturation, the expression of two surface antigens identifying distinct steps of leukocyte differentiation (CD15 and CD34) was studied by flow cytometry in correlation with DNA content in 16 c...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Campos L,Ffrench M,Guyotat D

    更新日期：1990-01-01 00:00:00

  • Allogeneic bone marrow transplantation improves the outcome of de novo AML with trilineage dysplasia (AML-TLD).

    abstract：:De novo acute myeloid leukemia (AML) with dysplastic features in erythroblasts, granulocytes and megakaryocytes, similar to those in myelodysplastic syndrome (MDS) has been described as AML with trilineage dysplasia (AML-TLD) since 1987. Several reports have suggested that AML-TLD is a subtype of de novo AML in adults...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401924

    authors： Taguchi J,Miyazaki Y,Yoshida S,Fukushima T,Moriuchi Y,Jinnai I,Matsuo T,Kuriyama K,Tomonaga M

    更新日期：2000-11-01 00:00:00

  • B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells.

    abstract：:B-cell acute lymphoblastic leukemia (B-ALL) is often associated with chromosomal translocations leading to the deregulation of proto-oncogenes. MicroRNAs can also be affected by chromosomal alterations and thus contribute to carcinogenesis. The microRNA, miR-125b-1, is overexpressed in B-ALL cases with the t(11;14)(q2...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2012.95

    authors： Puissegur MP,Eichner R,Quelen C,Coyaud E,Mari B,Lebrigand K,Broccardo C,Nguyen-Khac F,Bousquet M,Brousset P

    更新日期：2012-10-01 00:00:00

  • DPP4 truncated GM-CSF and IL-3 manifest distinct receptor-binding and regulatory functions compared with their full-length forms.

    abstract：:Dipeptidylpeptidase 4 (DPP4/CD26) enzymatically cleaves select penultimate amino acids of proteins, including colony-stimulating factors (CSFs), and has been implicated in cellular regulation. To better understand the role of DPP4 regulation of hematopoiesis, we analyzed the activity of DPP4 on the surface of immature...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.98

    authors： O'Leary HA,Capitano M,Cooper S,Mantel C,Boswell HS,Kapur R,Ramdas B,Chan R,Deng L,Qu CK,Broxmeyer HE

    更新日期：2017-11-01 00:00:00

  • Down-regulation of c-myc gene is not obligatory for growth inhibition and differentiation of human myeloid leukemia cells.

    abstract：:Suppression of c-myc expression is observed during induced differentiation of several myeloid cell lines and it has been attributed to the cell growth arrest that accompanies terminal differentiation. To dissect the role of c-Myc in the proliferation-differentiation switch we have studied c-myc expression in K562 cell...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Gómez-Casares MT,Delgado MD,Lerga A,Crespo P,Quincoces AF,Richard C,León J

    更新日期：1993-11-01 00:00:00

  • Chemical genomic screening identifies LY294002 as a modulator of glucocorticoid resistance in MLL-rearranged infant ALL.

    abstract：:Successful treatment results for MLL-rearranged Acute Lymphoblastic Leukemia (ALL) in infants remain difficult to achieve. Significantly contributing to therapy failure is poor response to glucocorticoids (GCs), like prednisone. Thus, overcoming resistance to these drugs may be a crucial step towards improving prognos...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2013.245

    authors： Spijkers-Hagelstein JA,Pinhanços SS,Schneider P,Pieters R,Stam RW

    更新日期：2014-04-01 00:00:00